Ramosetron

Chemical compound
  • None
Pharmacokinetic dataElimination half-life5.8 hoursIdentifiers
  • (1-Methyl-1H-indol-3-yl)[(5R)-4,5,6,7-tetrahydro-1H-benzimidazol-5-yl]methanone
CAS Number
  • 132036-88-5 checkY
  • HCl: 132907-72-3 checkY
PubChem CID
  • 108000
IUPHAR/BPS
  • 2301
  • HCl: 2305
ChemSpider
  • 97112 ☒N
UNII
  • 7ZRO0SC54Y
  • HCl: 9551LHD87E checkY
KEGG
  • D02016 ☒N
ChEMBL
  • ChEMBL1643895 ☒N
CompTox Dashboard (EPA)
  • DTXSID0043842 Edit this at Wikidata
Chemical and physical dataFormulaC17H17N3OMolar mass279.343 g·mol−13D model (JSmol)
  • Interactive image
  • CN1C=C(C2=CC=CC=C21)C(=O)[C@@H]3CCC4=C(C3)NC=N4
InChI
  • InChI=1S/C17H17N3O/c1-20-9-13(12-4-2-3-5-16(12)20)17(21)11-6-7-14-15(8-11)19-10-18-14/h2-5,9-11H,6-8H2,1H3,(H,18,19)/t11-/m1/s1 ☒N
  • Key:NTHPAPBPFQJABD-LLVKDONJSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Ramosetron (INN) is a serotonin 5-HT3 receptor antagonist for the treatment of nausea and vomiting.[1] Ramosetron is also indicated for a treatment of "diarrhea-predominant irritable bowel syndrome in male and women".[2] In India it is marketed under the brand name of Ibset.

It is only licensed for use in Japan and selected Southeast Asian countries. In Japan it is sold under the trade name Irribow.[3][4] and in India as Ibset . 'Elsewhere it is commonly sold under the trade name Nasea and in India as Nozia (150 μg/mL injection & 100 μg oral tablet).[5] While ramosetron itself may relief diarrhea for IBS patients, all the above tablets contain lactose, making them unsuitable for an IBS treatment in most cases.

References

  1. ^ Fujii Y, Saitoh Y, Tanaka H, Toyooka H (February 2000). "Ramosetron for preventing postoperative nausea and vomiting in women undergoing gynecological surgery". Anesth. Analg. 90 (2): 472–5. doi:10.1097/00000539-200002000-00043. PMID 10648342.
  2. ^ "2008 News Releases - Astellas Pharma Inc". www.astellas.com.
  3. ^ Summary in Japanese. Retrieved on September 4, 2012.
  4. ^ "2013 News Releases | Astellas Pharma Inc". www.astellas.com. Retrieved 2018-04-06.
  5. ^ Abridged prescribing information — Nasea (MIMS Philippines)[permanent dead link]. Retrieved on June 13, 2008.
  • v
  • t
  • e
5-HT3 serotonin ion
channel antagonists5-HT serotonin G-protein
receptor antagonistsCB1 agonists
(cannabinoids)D2/D3 antagonistsH1 antagonists
(antihistamines)mACh antagonists
(anticholinergics)NK1 antagonistsOthers
  • v
  • t
  • e
Drugs for
functional
bowel
disorders
Antimuscarinics
Tertiary
amino group
Quaternary
ammonium
compounds
Phosphodiesterase
inhibitors
Acting on
serotonin receptors
Other
Belladonna
and derivatives
(antimuscarinics)
Propulsives
  • v
  • t
  • e
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
  • See also: Receptor/signaling modulators
  • Adrenergics
  • Dopaminergics
  • Melatonergics
  • Monoamine reuptake inhibitors and releasing agents
  • Monoamine metabolism modulators
  • Monoamine neurotoxins
Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e